Crispr Therapeutics AG (NASDAQ:CRSP) – Analysts at Oppenheimer increased their FY2019 earnings per share estimates for Crispr Therapeutics in a research note issued to investors on Monday, November 25th, Zacks Investment Research reports. Oppenheimer analyst S. Tuerkcan now anticipates that the company will post earnings of $0.59 per share for the year, up from their previous estimate of $0.58. Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 target price on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Chardan Capital reiterated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Finally, BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $69.54.

NASDAQ CRSP traded up $0.38 during trading on Wednesday, hitting $66.03. 1,136,382 shares of the stock traded hands, compared to its average volume of 712,154. The company has a market capitalization of $3.72 billion, a P/E ratio of -19.19 and a beta of 3.31. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a 50-day simple moving average of $58.41 and a 200-day simple moving average of $48.30. Crispr Therapeutics has a 12-month low of $22.22 and a 12-month high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Benjamin Edwards Inc. boosted its holdings in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Crispr Therapeutics by 13.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after purchasing an additional 343 shares in the last quarter. Traynor Capital Management Inc. raised its position in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after purchasing an additional 375 shares in the last quarter. Commonwealth Equity Services LLC raised its position in Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after purchasing an additional 386 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in Crispr Therapeutics by 7.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after purchasing an additional 467 shares in the last quarter. Institutional investors own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What is the Federal Reserve?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link